HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Nelfinavir

HCID 64143
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
159989-64-7
Standard SMILES
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
InChIKey
QAGYKUNXZHXKMR-HKWSIXNMSA-N
Molecular formula
C32H45N3O4S
Average molar mass
567.8 g/mol
Monoisotopic mass
567.3130781

Overview

Nelfinavir is an aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. It has a role as an antineoplastic agent and a HIV protease inhibitor. It is a member of benzamides, an organic heterobicyclic compound, a member of phenols, a secondary alcohol, an aryl sulfide and a tertiary amino compound. It is a conjugate base of a nelfinavir(1+).

Names & identifiers

Preferred name
Nelfinavir
IUPAC
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
English name
NELFINAVIR
Molecular formula
C32H45N3O4S
Molecular weight
567.78

Names & synonyms

nelfinavir159989-64-7nelfinavirum(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamideHO3OGH5D7INSC-747167CHEBI:7496DTXSID50350803-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-(3S,4aS,8aS)-N-tert-butyl-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-phenylsulfanylbutyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamideRefChem:57161DTXCID3015080
Show more names
AG 1341nefinavirNELFINAVIR-12Nelfinavir D58a-beta))-a-betNELFINAVIR iMpurityNELFINAVIR USP/EP/BPNelfinavir (AG-1341)Nelfinavir (AG-1343)
J05AE04ViraceptViracept (TN)1ohrNELFINAVIR MESYLATE AG1343Nelfinavir (INN)AG-1343Met-SDF-1.beta. & Nelfinavir

Properties

Computed structural propertiesFilling in

XLogP
5.7
Topological polar surface area
127 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
6
Rotatable bonds
10
Heavy atoms
40
Formal charge
0
Complexity
829

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 items

6

4.0

Solubility · 2 items

Slightly soluble

1.91e-03 g/L

Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Protease Inhibitors
Melting Point349.84 °C
Physical DescriptionSolid

Physicochemical properties

Melting point
185 · 185-186 °C
Boiling point
786.8 · 786.8±60.0 °C(Predicted)
alpha
-119.23 ° · D -119.23° (c = 0.26 in methanol)
Density
1.22 · 1.22±0.1 g/cm3(Predicted)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Hepatotoxicity · 1 item

Some degree of serum aminotransferase elevation occurs in a high proportion of patients taking nelfinavir containing antiretroviral regimens. Moderate-to severe elevations in serum aminotransferase levels (>5 times the upper limit of normal) are found in only 3% to 10% of patients, although rates may be higher in patients with HIV-HCV coinfection. These elevations are usually asymptomatic and self-limited and can resolve even with continuation of the medication. Clinically apparent acute liver injury due to nelfinavir is rare. The few cases that have been reported have arisen after 1 to 8 weeks of starting nelfinavir, and the pattern of serum enzyme elevations has not been reported, but is likely to have been hepatocellular (Case 1). Signs of hypersensitivity (fever, rash, eosinophilia) can occur as can autoantibody formation but these features are not very prominent. The acute liver injury due to nelfinavir is usually self-limited, but it can be severe, and isolated cases of acute liver failure have been reported to the sponsor, although not in great detail. In HBV or HCV coinfected patients, some instances appear to be due to exacerbation of the underlying chronic liver disease, perhaps as a result of sudden immune reconstitution. Nelfinavir therapy has not been clearly linked to lactic acidosis and acute fatty liver that is reported in association with several nucleoside analogue reverse transcriptase inhibitors used to treat HIV infection.

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

nelfinavir

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Toxicity
rat,LD,oral,> 5gm/kg (5000mg/kg),Toxicologist. Vol. 42, Pg. 55, 1998.
Signal word
Warning

Chemistry & industry

Pharmacology

ATC Code · 2 items

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingNelfinavir in serum is extensively protein-bound (>98%).
Pharmacodynamics · 1 item

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of Action · 1 item

HIV viral protease is an important enzyme for HIV maturation and pathogenicity since HIV produces its structural and key proteins in the form of a polyprotein that needs to be cleaved by a protease. HIV protease is synthesized as part of the Gag-pol polyprotein, where Gag encodes for the capsid and matrix protein to form the outer protein shell, and Pol encodes for the reverse transcriptase and integrase protein to synthesize and incorporate its genome into host cells. The Gag-pol polyprotein undergoes proteolytic cleavage by HIV protease to produce 66 molecular species which will assume conformational changes to become fully active. Inhibition of protease, therefore, prevents HIV virion from fully maturing and becoming infective. Nelfinavir is a competitive inhibitor of the HIV protease by reversibly binding to the active site of the enzyme, preventing it from interacting with its substrate to produce mature and infectious viral particles.

Biological Half-LifeThe terminal half-life in plasma was typically 3.5 to 5 hours.
Metabolism/Metabolites · 2 items

Unchanged nelfinavir comprised 82-86% of the total plasma radioactivity after a single oral 750 mg dose of 14C-nelfinavir. In vitro, multiple cytochrome P-450 enzymes including CYP3A and CYP2C19 are responsible for the metabolism of nelfinavir. One major and several minor oxidative metabolites were found in plasma. The major oxidative metabolite has in vitro antiviral activity comparable to the parent drug.

Related reactions

23 records
New reaction record
HRID 346872 reaction equation
HRID 346872As product
HRID 380731 reaction equation
HRID 380731As reactant
HRID 380732 reaction equation
HRID 380732As reactant
HRID 384737 reaction equation
HRID 384737As reactant
HRID 384738 reaction equation
HRID 384738As reactant
HRID 384739 reaction equation
HRID 384739As reactant
HRID 384740 reaction equation
HRID 384740As reactant
HRID 384741 reaction equation
HRID 384741As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
159989-64-7
PubChem CID
64143
DTXSID
DTXSID5035080
ChEMBL
CHEMBL584
ChEBI
CHEBI:7496
UNII
HO3OGH5D7I
Nikkaji
J1.642.472B
storage temp.
2 · under inert gas (nitrogen or Argon) at 2–8 °C
solubility
20.45 mg/mL · ≥ 20.45mg/mL in Ethanol
form
Powder
pka
1 · pKa1 6.0; pKa2 11.06(at 25℃)
color
White to off-white
Water Solubility
7 g/L · 7g/L(temperature not stated)
FDA UNII
3 OGH5D7I · HO3OGH5D7I
ATC code
5 AE04 · J05AE04
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302
Precautionary statements
501 · P501-P270-P264-P301+P312+P330
Toxicity
5 gm/kg · rat,LD,oral,> 5gm/kg (5000mg/kg),Toxicologist. Vol. 42, Pg. 55, 1998.
Symbol(GHS)
GHS07
Hazard statements
H302
Precautionary statements
P501-P270-P264-P301+P312+P330

Nelfinavir has known human metabolites that include 3,4-Dihydroxynelfinavir and Nelfinavir hydroxyl-t- butylamide.

FDA Pharmacological Classification · 6 items

HO3OGH5D7I

NELFINAVIR

Mechanisms of Action [MoA] - HIV Protease Inhibitors

Established Pharmacologic Class [EPC] - Protease Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors

Nelfinavir is a Protease Inhibitor. The mechanism of action of nelfinavir is as a HIV Protease Inhibitor and Cytochrome P450 3A Inhibitor.

MeSH Pharmacological ClassificationInhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
Absorption, Distribution and Excretion · 4 items

Well absorbed following oral administration.

The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.

The apparent volume of distribution following oral administration of nelfinavir was 2-7 L/kg.

Oral clearance estimates after single doses (24-33 L/h) and multiple doses (26-61 L/h) indicate that nelfinavir is a drug with medium to high hepatic bioavailability.

Cellular LocationsCytoplasm

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >10

Applications

UsesAntiviral.

Additional notes

DefinitionChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.